To evaluate the impact of MCLA-145 treatment in the context of a more heterogenous T cell population, we engrafted NSG mice with human CD34+ hematopoietic stem cells and then implanted the PD-L1 expressing human MDA-MB-231 breast cancer line (Fig. 4f). Here, CD34 is linked to breast cancer.